Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …

Conspectus Nuclear medicine leverages radioisotopes of a wide range of elements, a
significant portion of which are metals, for the diagnosis and treatment of disease. To …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Targeted radiopharmaceutical therapy with alpha-particle emitters (αRPT) is advantageous
in cancer treatment because the short range and high local energy deposition of alpha …

The approval of 223 RaCl 2 for cancer therapy in 2013 has heralded a resurgence of
interest in the development of α-particle emitting radiopharmaceuticals. In the last decade …

Introduction In the last decade, two new radionuclide-based therapies, 223Radichloride and
radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA), have been …

The meeting and merging between innovative nanotechnological systems, such as
nanoparticles, and the persistent need to outperform diagnostic-therapeutic approaches to …